IBA, the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announces it has signed a contract for the supply of a Proteus ONE compact proton therapy solution to be installed at the MacKay Memorial Hospital in New Taipei City, Taiwan. This is the fourth order of a Proteus ONE system in Taiwan, further reinforcing IBA’s position as the undisputed market leader.
The contract includes the delivery and installation of a Proteus ONE system as well as a comprehensive Quality Assurance package from IBA Dosimetry. As the market-leading compact proton therapy system, Proteus ONE is designed to evolve and incorporate the latest technological advancements, ensuring that IBA users continue to benefit from state-of-the-art innovation. The system will also feature DynamicARC beam delivery capabilities, pending regulatory clearance. MacKay Memorial Hospital expects to start treating patients in 2029.
Olivier Legrain, Chief Executive Officer of IBA, commented: “We are delighted to secure this new Proteus ONE contract, the second in Taiwan in less than a year. The growing interest in our proton therapy solutions across Asia is a testament to the strength of our innovation strategy and our commitment to close partnerships. This success further consolidates IBA’s position as the undisputed leader in the global proton therapy market and demonstrates our dedication to making this cutting-edge technology accessible to more patients worldwide. We look forward to working closely with the MacKay Memorial Hospital team to ensure that cancer patients in Taiwan can benefit from the most advanced treatment options available.”
Dr Chun-Hao Chen, MD, PhD, Director, Department of Radiation Oncology at the MacKay Memorial Hospital, added: “We are proud to partner with IBA to bring this advanced technology to Taiwan. The installation of the Proteus ONE system at MacKay Memorial Hospital will significantly enhance our ability to provide state-of-the-art cancer treatment to our patients. This collaboration marks a major milestone in our commitment to delivering world-class care and expanding access to innovative therapies for the local community.”
